hit counter
Akcea Therapeutics, Inc. (AKCA) Stock News Sentiment & Price - Sentifly
AKCA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Akcea Therapeutics, Inc. (AKCA)

USA
Biotechnology
NASDAQ
AKCA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AKCA Latest news
Benzinga
Neutral
Ionis Axes Akcea's 70% Workforce Under Restructuring Plan
2021-04-07 07:15

Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”) for Tegsedi in North America. Tegsedi is indicated for polyneuropathy (a condition where multiple peripheral nerves become damaged) in adults with hereditary transthyretin amyloidosis.

Seeking Alpha
Positive
Ionis With Akcea: Still A Bargain
2020-10-21 02:08

Ionis With Akcea: Still A Bargain

PRNewsWire
Neutral
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND
2020-09-26 04:05

NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ionis...

PRNewsWire
Neutral
Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ:
2020-09-25 16:55

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AKCA to Ionis for $18.15 per share in cash. If you are a AKCA investor, and would like...

Business Wire
Neutral
WAYLIVRA?® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England
2020-09-18 03:00

LONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc.

PRNewsWire
Neutral
Kaskela Law LLC Announces Stockholder Investigation of Akcea Therapeutics, Inc. (AKCA) and Encourages Investors to Contact the Firm
2020-09-05 08:30

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc.

Business Wire
Neutral
PRNewsWire
Neutral
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, Inc. - AKCA
2020-09-01 17:05

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Akcea Therapeutics, Inc.

Zacks Investment Research
Neutral
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
2020-09-01 10:14

Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.

Zacks Investment Research
Negative
Akcea Therapeutics (AKCA) Reports Q2 Loss, Misses Revenue Estimates
2020-08-04 19:25

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Loading more news...